Active substance: no-carrier-added (n.c.a.) Lutetium (177Lu) chloride
EndolucinBeta® is a radiopharmaceutical precursor and it is indicated for the radiolabeling of disease-specific carrier molecules which have been specifically developed for radiolabeling with this radionuclide. The emerging radio conjugate is applied in Targeted Radionuclide Therapy, frequently in cancer treatment. EndolucinBeta® has a half-life of 6.647 days and provides the specific activity of more than 3,000 GBq/mg at Activity Reference Time (ART). EndolucinBeta® contains no metastable 177mLu.